for SCC development in patients. Clearly, their findings must be confirmed in a larger cohort of RDEB patients afflicted with SCCs. However, their work highlights the importance of molecular epidemiology in patients to ascertain the relevancy of findings in experimental models of skin tumor development.
Of course, it is possible that the requirement of NC1 expression for SCC development is restricted to a subset of RDEB patients in which Ha-Ras mutations occur. In sporadic SCCs Ras mutations are infrequent and typically occur late in tumor progression (Campbell et al., 1993; Clark et al., 1993) . Unfortunately, the activation state of HaRas in RDEB-associated SCCs is currently unknown. If a high frequency of Ras mutations should be prevalent in RDEBassociated SCCs, it would be of interest to determine whether the tumors formed in the absence of collagen VII expression exhibit deregulated signaling pathways normally dependent on the presence of either collagen VII or the NC1 domain (Rodeck et al., 2007) . Regardless of the results of future efforts to resolve these issues, expression of the NC1 domain of collagen VII alone is not likely to provide a reliable diagnostic tool to identify patients at risk of SCC development. Instead, collagen VII joins a long list of extracellular matrix components that have been implicated in SCC development at the microenvironment of the tumor-host interface, including collagen IV, collagen I, fibronectin, and laminin 332 (formerly laminin 5) (Abelev and Lazarevich, 2006; Marinkovich, 2007) . Much like these, collagen VII may act as a "modifier" of the transformed state by enhancing the malignant potential of initiated keratinocytes. Yet none of these extracellular matrix components is likely to be an absolute requirement for tumor progression.
RDEB, more so than less aggressive forms of EB, is characterized by chronic wound healing and excessive scar formation that last decades before SCCs are manifest. An interesting parallel to SCCs arising in continuously remodeling scar tissue is Marjolin's ulcers-SCCs that typically arise in burn scars many years after the initial scarring event (Phillips et al., 1998) . Interestingly, these SCCs are also very aggressive and invasive, much like RDEB-associated SCCs. These parallels raise the question of whether, regardless of collagen VII/NC1 expression status, chronic wound healing represents the driving force for the development of highly malignant SCCs in both the general population and RDEB patients.
CONFLICT OF INTEREST
The authors state no conflict of interest. (Stang and Jöckel, 2004) . Boyle et al. (2004) noted, "There is little information systematically collected and available regarding nonmelanoma skin cancer in populations although there have been some very recent publications giving insights into the epidemiology of this topic." Lewis and Weinstock (2007, this issue) provide new insights into the epidemiology of NMSC and pay special attention to the NMSC mortality of the genital skin. Although black men in the United States have a lower mortality rate of nongenital NMSC than white men, they have a higher mortality rate of genital NMSC than white men. This difference diminished from 1969 through 2000. Among white and black women, the mortality rates of genital NMSC were very similar (Lewis and Weinstock, 2007) .
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Generally, differences in mortality rates may be due to differences in disease risk (incidence) and/or of prognosis (survival). Although the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program has data for only a fraction (currently 26%) of the US population) (Ries et al., 2006) , an incidence and relative survival-trend analysis of genital NMSC by ethnicity could give additional clues to the reasons for the differences observed between black and white men and women regarding genital NMSC. For example, incidence-trend analyses of vulvar cancer (ICD-9: 184. 1-8) in East Germany during 1976-1989 and 1998-2002 (5,121 registered cases) show very stable rates of about 15 per 100,000 (World Standard Population) (Stang et al., 2005) . If a similar stable incidence pattern is observed in the United States, the decline in mortality of genital NMSC among women could be attributed to an improvement of survival. Stage-specific incidence and relative survival analyses of genital NMSC could show the degree to which earlier detection (i.e., lower stage at diagnosis) and/ or more efficient therapies contributed to the mortality decline over time. The same kind of analysis by ethnicity might help explain the observed differences of NMSC mortality among black and white people in the United States.
Lewis and Weinstock used the results of their Rhode Island follow-back study to modify their ICD-based definition of NMSC-related deaths. Cancers coded as ICD-9 173.4 (NMSC of the scalp and skin of neck) were excluded from their definition because their follow-back study showed that those coded deaths were often caused by squamous cell carcinoma of mucosal surfaces (Lewis and Weinstock, 2004) . In addition, some cancers that originate from the border between skin and mucosa-that is, vulvar skin cancer (ICD-9: 184 excluding vagina ICD-9 184.0), perianal skin (ICD-9: 154.3), and malignant neoplasms of the vermilion border of the lips (ICD-9: 140.0, 140.1, 140.9)-were included in their definition. Non-AIDSrelated Kaposi's sarcoma (ICD-9: 176.0) was also included.
If we assume that the Rhode Island results are generalizable to the US-wide mortality data, the application of their modified NMSC definition is appropriate. However, it is unknown whether findings from the Rhode Island followback study based on 239 deaths are generalizable to routine mortality statistics of other non-US health care systems. This generalization is reasonable only if a similar extent of miscoding cause of death by calendar time and age occurred. Unfortunately, accuracy studies of cause-of-death information on skin cancer from countries other than the United States are scant. In addition, in many countries mortality data over long calendar periods are not provided on the four-digit level of the ICD codes and therefore Lewis and Weinstock's refined definition cannot be applied to these data.
For these reasons, Lewis and Weinstock also provided the standard ICD-based definition of NMSC death coded ICD-9 173.0-173.9. These data can be compared with data from other countries if the same age standard for the mortality rates is used and if one assumes that a similar degree of miscoding by calendar year and age occurred. Figure 1 presents a comparison of NMSC mortality time trends in the United States (white people only) with those in West Germany (both US 2000 population standard) (Stang and Jöckel, 2004) . Among men, the mortality rate of NMSC was continuously higher in the United States than in West Germany. Interestingly, mortality rates due to NMSC among white women were higher in West Germany than in the United States in the early 1970s. West Germany showed a more or less monotonic decrease over time among both men and women. In contrast, the mortality due to NMSC in the United States showed sharp increases from 1981 to 1988, mainly among men under 60 years of age. This temporary increase is most likely due to AIDS-related Kaposi's sarcomas, which at the time were coded under NMSC (ICD-9: 173) (Lewis and Weinstock, 2007) . However, starting in the 1990s AIDS-related Kaposi's sarcomas were correctly coded (up to 1998 in the US: ICD-9, special code: 176.0; since 1999: ICD-10: C46.0) and more recent mortality rates of NMSC (since 1999 coded according to ICD-10: C44) are not lower than those in the early 1970s in the United States. In Germany, the HIV epidemic occurred considerably later and with a smaller magnitude than in the United States and therefore the temporary NMSC mortality increase due to AIDS-related Kaposi's sarcoma was not observed.
Lewis and Weinstock's follow-back study also revealed that tumors miscoded as NMSC occurred more frequently among the younger population (52-74% among people aged 0-74 years). Among the elderly (75+ years), miscoding occurred considerably less often (27-30%). A more accurate comparison of NMSC mortality in the United States and West Germany may therefore be possible among the elderly because miscoding occurs less frequently and AIDS-related Kaposi's sarcoma plays only a marginal role. Figure 2 displays the age-standardized NMSC mortality rates of white people 65 years and older in the United States and West Germany. Among both white men and white women in the United States, NMSC mortality rates declined from 1968 to 1979. Thereafter the rates remained fairly stable. AIDS-related Kaposi's sarcoma did not result in a sharp increase in NMSC in the 1980s in the United States. The introduction of the ICD-10 in the United States in 1999 coincides with a slight increase in NMSC mortality, especially among men.
The observed West German decline of the NMSC age-standardized mortality rate is due mainly to a strong decline in NMSC among people aged 80 years or older (Stang and Jöckel, 2004) . A comparison of the NMSC mortality rate among people 80 years or older between West Germany and the United States reveals a more similar pattern of decline (Figure 3) . NMSC mortality rates declined up to the end of the 1970s in both countries and among both white men and white women. Thereafter, the rates in the United States remained stable but further declined in West Germany. Interestingly, up to the mid 1990s, NMSC rates among women were higher in West Germany than in the United States.
Cancers at the border of the skin can pose a diagnostic problem because the histology of these cancers may not allow determination of the origin of the cancers, especially if carcinomas are undifferentiated and diagnosed at late stages. For example, 30.1% of all registered vulvar cancers other than melanoma in the German Democratic Republic from 1976 to 1989 had penetrated the organ border at the time of diagnosis (Stang et al., 2005) . The degree of misclassification of cancers at the border of the skin is thus difficult to quantify and may be dependent on a variety of factors, including diagnostic opportunities such as detail of histopathological assessment and stage of diagnosis, which most likely have changed over recent decades. Another problem related to cancers of the border of the skin is ICD-miscoding of these tumors, especially if cause-of-death information is imprecise. For example, cancers of the vermillion of the lips (ICD-9: 140.0-140.1) can be easily miscoded as either skin cancer of the lips (ICD-9: 173.0), cancer of the inner aspect of the lips (ICD-9: 140.4-140.5), or lip cancer that overlaps two or more subsites within the three-digit rubric (ICD-9: 140.8). in their definition of NMSC (Lewis and Weinstock, 2007) . Is routine causeof-death information accurate enough to allow correct distinction between these subcategories?
The Rhode Island follow-back study did not assess the accuracy of deaths coded as NMSC of the lips (ICD-9: 140.0-140.1 and 140.9) or perianal skin (ICD-9: 154.3) and leaves unanswered the question of whether inclusion of these deaths in the definition of NMSC death is appropriate (Lewis and Weinstock, 2004) .
In conclusion, Lewis and Weinstock provided important new insights into the mortality of genital NMSC. These data are a good starting point for more detailed analyses of the (overall and stage-dependent) incidence and survival of these tumors, which could give clues regarding the observed mortality time trends of genital NMSC in the United States.
